NASDAQ:IRWD

Ironwood Pharmaceuticals Competitors

$10.73
+0.07 (+0.66 %)
(As of 04/21/2021 01:08 PM ET)
Add
Compare
Today's Range
$10.61
Now: $10.73
$10.75
50-Day Range
$9.53
MA: $10.72
$11.53
52-Week Range
$8.63
Now: $10.73
$12.55
Volume20,395 shs
Average Volume2.10 million shs
Market Capitalization$1.73 billion
P/E Ratio15.55
Dividend YieldN/A
Beta1.46

Competitors

Ironwood Pharmaceuticals (NASDAQ:IRWD) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying IRWD stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Ironwood Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Earnings & Valuation

This table compares Ironwood Pharmaceuticals and Amgen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ironwood Pharmaceuticals$428.41 million4.03$21.50 million$0.5519.51
Amgen$23.36 billion6.37$7.84 billion$14.8217.45

Amgen has higher revenue and earnings than Ironwood Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

75.2% of Amgen shares are held by institutional investors. 2.4% of Ironwood Pharmaceuticals shares are held by company insiders. Comparatively, 0.4% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Ironwood Pharmaceuticals and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ironwood Pharmaceuticals04102.20
Amgen091402.61

Ironwood Pharmaceuticals currently has a consensus price target of $11.40, suggesting a potential upside of 6.24%. Amgen has a consensus price target of $261.1429, suggesting a potential upside of 0.96%. Given Ironwood Pharmaceuticals' higher possible upside, equities analysts plainly believe Ironwood Pharmaceuticals is more favorable than Amgen.

Volatility & Risk

Ironwood Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Ironwood Pharmaceuticals and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ironwood Pharmaceuticals27.77%-240.80%27.05%
Amgen29.42%95.55%15.52%

Summary

Amgen beats Ironwood Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Gilead Sciences and Ironwood Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Ironwood Pharmaceuticals27.77%-240.80%27.05%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Gilead Sciences and Ironwood Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences191302.52
Ironwood Pharmaceuticals04102.20

Gilead Sciences presently has a consensus target price of $97.68, suggesting a potential upside of 46.60%. Ironwood Pharmaceuticals has a consensus target price of $11.40, suggesting a potential upside of 6.24%. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Gilead Sciences is more favorable than Ironwood Pharmaceuticals.

Valuation & Earnings

This table compares Gilead Sciences and Ironwood Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.74$5.39 billion$6.1410.85
Ironwood Pharmaceuticals$428.41 million4.03$21.50 million$0.5519.51

Gilead Sciences has higher revenue and earnings than Ironwood Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 2.4% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Gilead Sciences has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Summary

Gilead Sciences beats Ironwood Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Vertex Pharmaceuticals and Ironwood Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Ironwood Pharmaceuticals27.77%-240.80%27.05%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Vertex Pharmaceuticals and Ironwood Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042112.88
Ironwood Pharmaceuticals04102.20

Vertex Pharmaceuticals presently has a consensus target price of $293.2083, suggesting a potential upside of 33.96%. Ironwood Pharmaceuticals has a consensus target price of $11.40, suggesting a potential upside of 6.24%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Vertex Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.

Valuation & Earnings

This table compares Vertex Pharmaceuticals and Ironwood Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.61$1.18 billion$4.2951.02
Ironwood Pharmaceuticals$428.41 million4.03$21.50 million$0.5519.51

Vertex Pharmaceuticals has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Summary

Vertex Pharmaceuticals beats Ironwood Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Regeneron Pharmaceuticals and Ironwood Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Ironwood Pharmaceuticals27.77%-240.80%27.05%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Regeneron Pharmaceuticals and Ironwood Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Ironwood Pharmaceuticals04102.20

Regeneron Pharmaceuticals presently has a consensus target price of $644.1739, suggesting a potential upside of 27.26%. Ironwood Pharmaceuticals has a consensus target price of $11.40, suggesting a potential upside of 6.24%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Ironwood Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.90$2.12 billion$21.4723.58
Ironwood Pharmaceuticals$428.41 million4.03$21.50 million$0.5519.51

Regeneron Pharmaceuticals has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Ironwood Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Institutional & Insider Ownership

83.5% of Biogen shares are owned by institutional investors. 0.5% of Biogen shares are owned by company insiders. Comparatively, 2.4% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Biogen and Ironwood Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Ironwood Pharmaceuticals27.77%-240.80%27.05%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Biogen and Ironwood Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5141202.23
Ironwood Pharmaceuticals04102.20

Biogen presently has a consensus target price of $303.3103, suggesting a potential upside of 13.25%. Ironwood Pharmaceuticals has a consensus target price of $11.40, suggesting a potential upside of 6.24%. Given Biogen's stronger consensus rating and higher possible upside, research analysts plainly believe Biogen is more favorable than Ironwood Pharmaceuticals.

Valuation & Earnings

This table compares Biogen and Ironwood Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.84$5.89 billion$33.577.98
Ironwood Pharmaceuticals$428.41 million4.03$21.50 million$0.5519.51

Biogen has higher revenue and earnings than Ironwood Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Summary

Biogen beats Ironwood Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Alexion Pharmaceuticals and Ironwood Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Ironwood Pharmaceuticals27.77%-240.80%27.05%

Analyst Ratings

This is a summary of recent ratings and price targets for Alexion Pharmaceuticals and Ironwood Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017412.27
Ironwood Pharmaceuticals04102.20

Alexion Pharmaceuticals presently has a consensus target price of $153.4286, suggesting a potential downside of 8.73%. Ironwood Pharmaceuticals has a consensus target price of $11.40, suggesting a potential upside of 6.24%. Given Ironwood Pharmaceuticals' higher possible upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Valuation and Earnings

This table compares Alexion Pharmaceuticals and Ironwood Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.44$2.40 billion$9.7417.26
Ironwood Pharmaceuticals$428.41 million4.03$21.50 million$0.5519.51

Alexion Pharmaceuticals has higher revenue and earnings than Ironwood Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Ironwood Pharmaceuticals on 11 of the 15 factors compared between the two stocks.


Ironwood Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$258.65+0.2%$149.21 billion$23.36 billion20.86Upcoming Earnings
Analyst Report
Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$66.63+0.4%$83.58 billion$22.45 billion68.69Analyst Report
Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$218.88+0.6%$56.98 billion$4.16 billion27.64Analyst Report
Analyst Revision
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$506.17+0.3%$54.04 billion$7.86 billion18.50Analyst Report
Biogen logo
BIIB
Biogen
1.9$267.83+2.0%$41.62 billion$14.38 billion8.87Upcoming Earnings
Analyst Report
Analyst Revision
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$168.11+0.9%$36.79 billion$4.99 billion39.28
Seagen logo
SGEN
Seagen
1.7$145.00+0.2%$26.25 billion$916.71 million57.09
Exact Sciences logo
EXAS
Exact Sciences
1.8$128.18+2.0%$21.24 billion$876.29 million-58.00Analyst Upgrade
Incyte logo
INCY
Incyte
1.6$84.10+0.6%$18.59 billion$2.16 billion-53.57
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$136.64+0.4%$15.96 billion$219.75 million-17.45Analyst Report
Novavax logo
NVAX
Novavax
1.2$213.45+2.5%$15.37 billion$18.66 million-40.89Insider Selling
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$78.46+1.3%$14.45 billion$1.70 billion17.95Analyst Report
Insider Selling
Repligen logo
RGEN
Repligen
1.5$215.50+1.6%$11.61 billion$270.24 million262.80Analyst Report
United Therapeutics logo
UTHR
United Therapeutics
1.5$210.81+1.5%$9.25 billion$1.45 billion19.94
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.52+0.4%$9.09 billion$788.10 million103.79Analyst Report
Analyst Revision
Exelixis logo
EXEL
Exelixis
1.9$24.71+0.8%$7.67 billion$967.78 million51.48Analyst Report
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$48.40+3.2%$6.71 billion$195.99 million302.50
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.45+0.7%$5.80 billion$1.12 billion86.35Analyst Report
Analyst Revision
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.22+0.7%$4.03 billion$806.43 million-9.52Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$65.23+0.6%$3.52 billion$1.11 billion20.97News Coverage
Gap Up
Alkermes logo
ALKS
Alkermes
1.2$20.37+1.0%$3.21 billion$1.17 billion-44.28Insider Selling
Analyst Revision
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$45.54+0.5%$3.16 billion$36.13 million-67.97
OPKO Health logo
OPK
OPKO Health
1.9$4.25+2.8%$2.77 billion$901.90 million-23.61
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.81+0.3%$2.59 billion$182.24 million-8.53Analyst Upgrade
Insider Selling
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$149.27+1.7%$2.44 billion$120.28 million-150.78Decrease in Short Interest
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.40+2.9%$2.05 billion$638.60 million-10.54Insider Selling
Gap Up
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$129.05+2.1%$2.02 billionN/A-11.66News Coverage
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$11.46+3.1%$1.97 billion$48.83 million-15.08
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.55+0.2%$1.66 billion$102.43 million-19.25
Codexis logo
CDXS
Codexis
1.3$23.63+3.1%$1.47 billion$68.46 million-67.51Analyst Report
Gap Up
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.45+1.7%$1.46 billion$82.27 million-18.17
Innoviva logo
INVA
Innoviva
1.4$12.04+0.5%$1.21 billion$261.02 million6.14News Coverage
MannKind logo
MNKD
MannKind
1.4$4.46+5.2%$1.05 billion$63.04 million-21.24Increase in Short Interest
News Coverage
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$9.23+3.1%$1.01 billion$35.22 million-6.74
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$24.70+4.2%$937.69 million$3.57 million-11.08
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.66+0.7%$908.31 million$227.19 million46.28Analyst Downgrade
Curis logo
CRIS
Curis
1.3$9.92+1.0%$898.72 million$10 million-12.10
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$24.00+1.4%$884.22 millionN/A0.00Gap Up
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.97+1.8%$704.45 million$322.07 million-4.73Upcoming Earnings
Decrease in Short Interest
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.68+0.6%$689.77 million$252 million-2.11
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.19+0.6%$682.20 million$150,000.00-4.56News Coverage
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.56+0.3%$603.93 million$59.29 million-23.73Increase in Short Interest
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.85+3.1%$592.69 million$143.01 million-1.12
Agenus logo
AGEN
Agenus
1.6$2.79+4.3%$547.53 million$150.05 million-2.56
Verastem logo
VSTM
Verastem
1.1$2.77+2.2%$465.22 million$17.46 million-1.96
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.96+1.7%$447.35 million$109.33 million-2.18
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.50+6.4%$446.17 million$22.27 million-4.17Analyst Report
Insider Buying
Analyst Revision
News Coverage
Gap Down
Geron logo
GERN
Geron
1.4$1.41+0.4%$445.94 million$460,000.00-4.01Decrease in Short Interest
XOMA logo
XOMA
XOMA
1.3$36.96+4.1%$398.98 million$18.37 million-33.30Increase in Short Interest
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$4.12+2.7%$380.58 million$36.63 million-4.85Analyst Report
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.